

STRAUMANN® EMDOGAIN™

BEFORE IT'S TOO LATE

NEW

EMDOGAIN™ 015
DESIGNED TO REBUILD



COMMITTED TO
SIMPLY DOING MORESM
FOR DENTAL PROFESSIONALS

"THE EMDOGAIN™ 015 SHOULD ENABLE THE CLINICIAN TO USE THE MATERIAL MORE OFTEN SINCE IT WILL BE MORE COST-EFFECTIVE WHEN ADDED TO BONE GRAFTING PROCEDURES."

DR. DAVID COCHRAN



TOOTH PRESERVATION WITH STRAUMANN® EMDOGAIN™

Emdogain is now available in a new package size containing 5 syringes with 0.15 ml. This allows for a cost-effective treatment of smaller defects and soft tissue grafting procedures. The addition of Emdogain 015 to our regenerative portfolio enables the clinician to select the right amount of Emdogain for use with various bone grafting materials*, providing the patient with the potential for an enhanced outcome.

5-15% OF POPULATION SUFFERS FROM SEVERE PERIODONTITIS THAT MAY LEAD TO TOOTH LOSS^{1,2}

Periodontitis treatment involves controlling the causative bacteria and inflammation, as well as subsequent regeneration of the lost periodontal hard and soft tissues in order to regain tooth attachment.

Biological guided regeneration

Straumann Emdogain supports the predictable regeneration of the lost periodontal hard and soft tissue caused by periodontitis, helping to save and preserve the tooth.³

Applying Straumann Emdogain to the cleaned root surface of the periodontally diseased tooth helps to regenerate the periodontium, which includes the cementum, periodontal ligament and alveolar bone.⁴⁻⁸

Regenerative surgery with Straumann® Emdogain™



Emdogain with periodontal surgery.

Courtesy of Prof. Carlos E. Nemcovsky, Tel-Aviv University



Emdogain in combination with a Caronally Advanced Flap (CAF).

Courtesy of Prof. Zucchelli, Bologna University

*Allograft, autograft, bone-derived xenograft, β -TCP or bioactive glass



BIOLOGICAL GUIDED REGENERATION FOR VARIOUS INDICATIONS

Straumann® Emdogain™ is indicated for:

1 Intrabony defects



2 Wide intrabony defects



In combination with bone graft materials in wide defects or where additional soft tissue support is needed.*

3 Furcation defects (Class II Mandibular furcation)



4 Recession defects



*Allograft, autograft, bone-derived xenograft, β -TCP or bioactive glass



The following steps describe how Straumann® Emdogain™ helps to regenerate the periodontium over time:



1 When Straumann® Emdogain™ is applied the enamel matrix derived proteins precipitate on the root surface to form a matrix layer.



2 The matrix stimulates the attraction and proliferation of mesenchymal cells from the healthy part of the periodontium.



3 The cells secrete natural and specific cytokines and autocrine substances promoting the necessary proliferation.



4 Supporting cells are attracted and differentiate into cementoblasts which start with the formation of the cement matrix in which the periodontal fibers will be fixed.



5 The newly formed cement layer increases in thickness, extending the periodontal ligament.



6 Within months, the defect fills with newly formed periodontal ligament.



7 As the periodontal ligament is formed, new bone continues to develop.



8 Straumann® Emdogain™ facilitates the regeneration of the complex dental structure of the periodontium, building a new functional attachment.

“STRAUMANN EMDOGAIN STIMULATES THE REGENERATION OF BOTH THE HARD AND SOFT TISSUES OF THE PERIODONTIUM AT THE SAME TIME.”


DR. DAVID COCHRAN

PREDICTABLE CLINICAL RESULTS



Confidence thanks to predictable clinical results

- Improved clinical results when treating patients with intrabony defects compared to OFD alone⁹
- Increased probability of complete root coverage achieved with a Coronally Advanced Flap (CAF) compared to CAF alone¹⁰
- More than 400 clinical publications scientifically document results with Straumann® Emdogain™ to have predictable clinical results



Percentage of patients with highly significant outcome (CAL gain of >4 mm) 1 year post-operative in the treatment of intrabony defects⁹


"BOTH THE SCIENTIFIC EVIDENCE AND MY PERSONAL EXPERIENCE SUPPORT THAT WITH THE APPROPRIATE CASE, STRAUMANN EMDOGAIN SIGNIFICANTLY IMPROVES ROOT COVERAGE COMPARED TO THE CORONALLY ADVANCED FLAP ALONE."

DR. MICHAEL K. MCGUIRE, DDS

MORE THAN 1 MILLION PATIENTS TREATED WORLDWIDE

Rely on long-term clinical experience

- Documented treatment success up to 10 years^{11,16}
- Improved attachment level maintained up to 5 years compared to baseline¹²
- Improved probing depth level maintained up to 5 years compared to baseline¹²



Significantly improved CAL and PD following OFD with Straumann® Emdogain™, measured up to 5 years¹² compared to baseline

Added value for your practice due to patient satisfaction

- Clinicians reported on enhanced periodontal wound healing when using Straumann® Emdogain™ compared to PGA carrier alone¹³
- Less patients with pain and swelling compared to traditional Guided Tissue Regeneration (GTR)¹⁴
- Designed to improve patient comfort compared to traditional OFD¹³, GTR¹⁴ or connective tissue graft (CTG)¹⁵ alone



Percentage of patients with pain** and swelling** 1 week post-operative in furcation treatment with GTR or Straumann® Emdogain™¹⁴

**Little, moderate and strong



STRAUMANN® EMDOGAIN

NOW AVAILABLE IN 3 SYRINGE SIZES FOR YOUR CONVENIENCE.



Straumann® Emdogain 0.15 ml

5 x Straumann® Emdogain 0.15 ml

Art. No. 075.099

Straumann® PrefGel 0.6 ml

5 x Straumann® PrefGel 0.6 ml

Art. No. 075.203

Straumann® Emdogain 0.3 ml

Multipack

3 x Straumann® Emdogain 0.3 ml and

3 x Straumann® PrefGel 0.6 ml

Art. No. 075.113

Straumann® Emdogain 0.7 ml

Multipack

3 x Straumann® Emdogain 0.7 ml and

3 x Straumann® PrefGel 0.6 ml

Art. No. 075.115

References

- ¹ AAP: Position Paper: Epidemiology of Periodontal diseases. *J Periodontol* 2005;76:1406-1419.
- ² Holtfreter B, Kocher T, Hoffmann T, Desvarieux M, Micheelis W. Prevalence of periodontal disease and treatment demands based on a German dental survey [DMS IV]. *J Clin Periodontol*. 2010;37:211-219.
- ³ Bosshardt DD. Biological mediators and periodontal regeneration: a review of enamel matrix proteins at the cellular and molecular levels *J Clin Periodontol* 2008; 35(Suppl. 8):87-105.
- ⁴ Pimentel SP, Sallum AW, Saldanha JB, Casati MZ, Nociti FH Jr, Sallum EA. Enamel matrix derivative versus guided tissue regeneration in the presence of nicotine: a histomorphometric study in dogs. *J Clin Periodontol*. 2006;33:900-907.
- ⁵ Bosshardt DD, Sculean A, Windisch P, Pjetursson BE, Lang NP. Effects of enamel matrix proteins on tissue formation along the roots of human teeth. *J Periodontol Res*. 2005;40:158-167.
- ⁶ Sallum EA, Pimentel SP, Saldanha JB, Nogueira-Filho GR, Casati MZ, Nociti FH, Sallum AW. Enamel Matrix Derivative and Guided Tissue Regeneration in the Treatment of Dehiscence-Type Defects: A Histomorphometric Study in Dogs *J Periodontol*. 2004;75:1357-1363.
- ⁷ Sakallioğlu U, Açikgöz G, Ayas B, Kiriloğlu T, Sakallioğlu E. Healing of periodontal defects treated with enamel matrix proteins and root surface conditioning - an experimental study in dogs *Biomaterials*. 2004;25:1831-1840.
- ⁸ Cochran DL, King GN, Schoolfield J, Velasquez-Plata D, Mellonig JT, Jones A. The effect of enamel matrix proteins on periodontal regeneration as determined by histological analyses. *J Periodontol*. 2003;74:1043-1055.
- ⁹ Tonetti MS, Lang NP, Cortellini P, Suvan JE, Adriaens P, Dubravec D, Fonzar A, Fourmousis I, Mayfield L, Rossi R, Silvestri M, Tiedemann C, Topoll H, Vangsted T, Wallkamm B. Enamel matrix proteins in the regenerative therapy of deep intrabony defects - A multicentre randomized controlled clinical trial *J Clin Periodontology* 2002; 29; 317-325.
- ¹⁰ Cairo F, Pagliaro U, Nieri M. Treatment of gingival recession with coronally advanced flap procedures: a systematic review. *J Clin Periodontol* 2008;35(Suppl 8):136-162.
- ¹¹ Sculean A, Kiss A, Miliuskaite A, Schwarz F, Arweiler NB, Hannig M. Ten-year results following treatment of intra-bony defects with enamel matrix proteins and guided tissue regeneration. *J Clin Periodontol* 2008;35:817-824.
- ¹² Heden G, Wennström JL. Five-Year Follow-Up of Regenerative Periodontal Therapy With Enamel Matrix Derivative at Sites With Angular Bone Defects *J Periodontol* 2006;77:295-301.
- ¹³ Wennstrom JL, Lindhe J. Some effects of enamel matrix proteins on wound healing in the dento-gingival region. *J Clin Periodontol* 2002;29:9-14.
- ¹⁴ Jepsen S, Heinz B, Jepsen K, Arjomand M, Hoffmann T, Richter S, Reich E, Sculean A, Gonzales JR, Bödeker RH, Meyle J. A randomized clinical trial comparing enamel matrix derivative and membrane treatment of buccal class II furcation involvement in mandibular molars. Part I: Study design and results for primary outcomes. *J Periodontol*. 2004;75:1150-1156.
- ¹⁵ McGuire, MK, Nunn M. Evaluation of human recession defects treated with coronally advanced flaps and either enamel matrix derivative or connective tissue. Part 1: Comparison of clinical parameters. *J Periodontol* 2003;74:1110-1125.
- ¹⁶ McGuire MK, Scheyer ET, Nunn M. Evaluation of human recession defects treated with coronally advanced flaps and either enamel matrix derivative or connective tissue: comparison of clinical parameters at 10 years. *J Periodontol*. 2012;83:1353-1362.

www.straumannusa.com

International Headquarters

Institut Straumann AG
Peter Merian-Weg 12
CH-4002 Basel, Switzerland
Phone +41 (0)61 965 11 11
Fax +41 (0)61 965 11 01

Straumann USA

Straumann USA, LLC
60 Minuteman Road
Andover, MA 01810
Phone 800/448 8168
978/747 2500
Fax 978/747 2490
www.straumannusa.com

Straumann Canada

Straumann Canada Limited
3115 Harvester Road, Suite 100
Burlington, ON L7N 3N8
Phone 800/363 4024
905/319 2900
Fax 905/319 2911
www.straumann.ca

© Straumann USA, LLC 2013. All rights reserved.

Straumann® and/or other trademarks and logos from Straumann® that are mentioned herein are the trademarks or registered trademarks of Straumann Holding AG and/or its affiliates. All rights reserved.

